ArticleNanoscale2020
An NIR-II/MR dual modal nanoprobe for liver cancer imaging.
Article in Nanoscale, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 63 citations in OpenAlex.
- Dual-modality theranostics probes: sintegrative strategies for precision management of oncologic malignancies.Life medicine · 2026Review
- GdACS applied materials & interfaces · 2025Article
- Luminescence Fingerprint of Intracellular NIR-II Gold Nanocluster Transformation: Implications for Sensing and Imaging.ACS nano · 2025Article
- NIR-II fluorescence in lung cancer: advancing precision diagnosis and image-guided therapy.Frontiers in chemistry · 2025Review
- NIR-II light in clinical oncology: opportunities and challenges.Nature reviews. Clinical oncology · 2024Review
- Near-Infrared-Responsive Rare Earth Nanoparticles for Optical Imaging and Wireless Phototherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Tracking tumor heterogeneity and progression with near-infrared II fluorophores.Exploration (Beijing, China) · 2023Review
- Research Progress on Up-Conversion Fluorescence Probe for Detection of Perfluorooctanoic Acid in Water Treatment.Polymers · 2023Review
- Near-infrared fluorescence imaging of hepatocellular carcinoma cells regulated by β-catenin signaling pathway.Frontiers in oncology · 2023Article
- A Rare-Earth Near-Infrared Nanoprobe for the Identification of Small Cell Lung Cancer.International journal of nanomedicine · 2023Article
- Research trends and hot spots in global nanotechnology applications in liver cancer: a bibliometric and visual analysis (2000-2022).Frontiers in oncology · 2023Article
- Review
- Changes in the Secondary Structure and Assembly of Proteins on Fluoride Ceramic (CeFACS applied bio materials · 2022Article
- Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2022Review
- Clearance pathways of near-infrared-II contrast agents.Theranostics · 2022Review
- Rapidly liver-clearable rare-earth core-shell nanoprobe for dual-modal breast cancer imaging in the second near-infrared window.Journal of nanobiotechnology · 2021Article
- Size-controlled bimodalScience and technology of advanced materials · 2021Article
- A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma.Annals of translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a malignancy of the liver worldwide and surgical resection remains the most effective treatment. However, it is still a great challenge to locate small lesions and define the border of diffused HCC even with the help of preoperative imaging examination. Here, we reported a rare-earth-doped nanoparticle NaGdF4:Nd 5%@NaGdF4@Lips (named Gd-REs@Lips), which simultaneously performed powerful functions in both magnetic resonance imaging (MRI) and second near-infrared fluorescence window imaging (NIR-II, 1000-1700 nm). Imaging studies on orthotopic models with xenografts established from HCC patients indicated that Gd-REs@Lips efficiently worked as a T2-weighted imaging contrast agent to increase the signal intensity difference between liver cancer tissues and surrounding normal liver tissues on MRI, and it can also serve as a negative NIR-II imaging contrast enabling the precise detection of liver cancer. More importantly, benefiting from the high sensitivity of NIR-II imaging, Gd-REs@Lips allowed the visualization of tiny metastasis lesions (2 mm) on the liver surface. It is expected that the dual NIR-II/MRI modal nanoprobe developed holds high potential to fill the gap between the preoperative imaging detection of cancer lesions and intra-operative guidance, and it further brings new opportunities to address HCC-related medical challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.